Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2005
10/04/2005US6951850 Dipeptide derivatives
10/04/2005US6951844 substituted 5-phenyl-2-naphthols; metabolic disorders
10/04/2005US6951658 administering mixtures of animal oils, lioleic acid, arginine, pyroglutamic acid, methyl vitamin B12 and calcium, for prophylaxis of neurodegenative diseases
10/04/2005US6951641 administering a dimeric nonionic X-ray contrast media selected from iotrolan and iodixannol to an eye of a mammal suffering allergic conjunctivtis and allergic rhinitis
10/04/2005US6951219 Treatment of hepatitis C using hyperthermia
09/2005
09/30/2005CA2499791A1 Angptl4/fiaf as marker for ppardelta modulation
09/29/2005WO2005090372A2 Platinum carboxylate anticancer compounds
09/29/2005WO2005090332A1 Substituted quinazoline or pyridopyrimidine derivative
09/29/2005WO2005089810A1 Method of inducing bone by transferring human osteogenetic factor gene with the use of electroporation method
09/29/2005WO2005089803A2 Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs
09/29/2005WO2005089802A1 Therapeutic agent for auris interna disorder containing il-6 antagonist as active ingredient
09/29/2005WO2005089801A1 Method of preventing ultraviolet ray-induced apoptosis
09/29/2005WO2005089800A1 PHARMACEUTICAL COMPOSITION CONTAINING hsHRD3
09/29/2005WO2005089779A2 Rapidly disintegrating taste-masked tablet
09/29/2005WO2005089762A2 Pharmaceutical composition of (+)-erythro-mefloquine and its use in the treatment of an inflammatory condition
09/29/2005WO2005089761A1 Combination for treating inflammatory diseases
09/29/2005WO2005089751A2 Use of metronidazole for preparing a pharmaceutical composition for treating a cutaneous inflammation
09/29/2005WO2005089750A2 Use of metronidazole for preparing a pharmaceutical composition for treating pathologies related to the b-type receptor of interleukin 8 and/or to a pacap type 1 receptor
09/29/2005WO2005089749A2 Use of metronidazole for preparing a pharmaceutical composition for treating a cutaneous vascularisation disorder
09/29/2005WO2005089748A1 Combination for treating inflammatory diseases
09/29/2005WO2005089742A1 Medicine for prevention or treatment of frequent urination or urinary incontinence
09/29/2005WO2005089738A2 Use and administration of bacterial efflux pump inhibitors
09/29/2005WO2005089731A2 Use of renin inhibitors in therapy
09/29/2005WO2005089721A1 In process conversion method for preparing tannate tablet, capsule or other solid dosage forms
09/29/2005WO2005089720A1 Valsartan tablets and the process for the preparation thereof
09/29/2005WO2005089714A1 Emulsion stabilizer
09/29/2005WO2005089522A2 Spermicidal and virucidal properties of various forms of sophorolipids
09/29/2005WO2005089503A2 Cd4-igg2 formulations
09/29/2005WO2005089100A2 Decontamination formulations for disinfection and sterilization
09/29/2005WO2005074460A3 Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
09/29/2005WO2005065669A8 Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
09/29/2005WO2005054440A3 A biomimetic composition reinforced by a polyelectrolytic complex of hyaluronic acid and chitosan
09/29/2005WO2005049142A3 Graduated estrogen contraceptive
09/29/2005WO2005039483A3 Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
09/29/2005WO2005009382A3 Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
09/29/2005WO2005009334A3 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof
09/29/2005WO2005003295A3 Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds
09/29/2005WO2004012662A3 Improved treatment of cancer with glutamine
09/29/2005WO2003074057A8 Anti-infective agents and/or immunomodulators used for preventive therapy following an acute cerebrovascular accident
09/29/2005US20050215722 Drug delivery compositions and medical devices containing block copolymer
09/29/2005US20050215647 N-methyl-3-hydroxy-4,4-dimethyl-2-(2'naphthyl)pentylamine; potent, wide-spectrum antidepressant and treating anxiety disorders
09/29/2005US20050215637 Tuberculosis treatment
09/29/2005US20050215633 Use of neurotoxic substances for the production of a means for the treatment of joint paint and method for application of said means
09/29/2005US20050215630 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
09/29/2005US20050215627 Application of substances acting as cascade inhibitors of the Raf/MEK/ERK signaling cascade for the production of a drug against DNA and RNA viruses
09/29/2005US20050215620 Method of treating amyloid beta precursor disorders
09/29/2005US20050215617 Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
09/29/2005US20050215592 Methods for assessing, improving, or maintaining urogenital health in postmenopausal woman
09/29/2005US20050215571 Therapeutic combination for cognititon enhancement and psychotic disorders
09/29/2005US20050215565 Using sulfonamides such as N-[N-(3-pyridinesulfonyl)-L-3,3-dimethyl-4-thiaprolyl]-O-[1-methylpiperazin-4-ylcarbonyl]-L-tyrosine isopropyl ester optionally with immunoglobulins, steroids, antiinflammatory agents
09/29/2005US20050215552 synergistic admnistration of a weight-loss promoting benz(is)oxazole anticonvulsant and a bupropion metabolite; hypotensive, antidiabetic, anticholesterol agents; norepinephrine or dopamine agonists
09/29/2005US20050215550 Pyrazole-derived kinase inhibitors and uses thereof
09/29/2005US20050215545 Methods of treating HIV infection
09/29/2005US20050215543 Methods of treating HIV infection
09/29/2005US20050215537 Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
09/29/2005US20050215535 Sequential SPRM/progestin treatment
09/29/2005US20050215533 Administering to mammal an effective amount of sulfaphenazole wherein the administered sulfaphenazole substantially reduces the amount of infracted tissue
09/29/2005US20050215532 Tetracycline compounds for treatment of cryptosporidium parvum related disorders
09/29/2005US20050215528 Gnrh agonist combination drugs
09/29/2005US20050215522 Blocks passage of the pathogen through lipid rafts in the membrane of a cell susceptible to the pathogen; especially for reducing the risk of infection with an enveloped immunodeficiency virus, T lymphotrophic virus or herpesvirus
09/29/2005US20050215521 Modafinil combination therapy for improving sleep quality
09/29/2005US20050215509 Method for inhibiting jnk-1 kinase activity by SCCA
09/29/2005US20050215500 aoaligonucleotides containing activated lymphocytes; antibody therapy; skin disorders; antiallergens
09/29/2005US20050215496 Preparation and diabetic use of Gibberellins
09/29/2005US20050215469 Reducing food intake; obesity; dietetics
09/29/2005US20050215451 Powdery product comprising crystalline beta-maltose monohydrate, its preparation, and uses
09/29/2005US20050214866 Apparatus comprising receptor immobilized on porous support for use as tool in diagnosing allergic diseases; immunotherapy
09/29/2005US20050214835 Diagnosis and treatment of myocardial failure
09/29/2005US20050214830 Recombinant g protein coupled receptor for use in identifying modulators for prevention and treatment of cell proliferative disorders
09/29/2005US20050214795 Polypeptide for use as diagnostic indicator of cell proliferative disorders; immunotherapeutics; antitumor agents
09/29/2005US20050214780 Using polymorphism in potassium channel interacting protein (KChIP1) as diagnostic indicator for pancreatic disorders
09/29/2005US20050214388 Multivitamin formulations containing controlled-release magnesium
09/29/2005US20050214387 Low-dose potassium supplementation for the prevention and treatment of hypertension
09/29/2005US20050214384 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
09/29/2005US20050214378 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
09/29/2005US20050214353 Matrix for administering ergoline compounds such as lisuride; restless leg syndrome; circadian rhythm disorders; Parkinson's disease
09/29/2005US20050214346 For reducing serum cholesterol by increasing high density lipoprotein concentration; hypercholesterolemia
09/29/2005US20050214341 Three dimensional, malleable cell culture; tissue engineering; pluripotent cells
09/29/2005US20050214299 Method of inhibiting stenosis and restenosis
09/29/2005US20050214296 Methods of modulating cytokine activity; related reagents
09/29/2005US20050214293 Containing heavy and light chain complementarity determining region 1,2 and 3 components of amino acid sequences 1-6; reduced immunogenicity; increased affinity and avidity; improved cell culturing
09/29/2005US20050214291 Treatment method
09/29/2005US20050214274 T-cells are contacted agents that ligate a cell surface; crosslinking by a second agent attached to a biodegradable supports; T-cells and biodegradable supports are suspended in a medium for parenteral infusion and packaged in container
09/29/2005US20050214273 Propionibacterium P-63 for use in direct fed microbials for animal feeds
09/29/2005US20050214271 for treating airway hyperreactivity and inflammation, atopic dermatitis, allergic conjunctivitis, rhinitis, sinusitis, hypersensitive pneumonia, extrinsic allergic alveolitis, urticaria, eczema, anaphylaxis, angioedema, migraines
09/29/2005US20050214266 Pretreating hematopoietic stem cells harvested from blood or bone marrow, tissue materials and/or organs prior to surgical implantation; preventing infections
09/29/2005US20050214262 Population of hematopoietic cells, made to exhibit a greater clonogenic potential, engraftment potential, immune system reconstitution potential and/or proportion of CD34+ positive cells by culturing with a transition metal compound that chelates copper such as tetraethylenepentamine
09/29/2005US20050214261 Method for treating a skin defect
09/29/2005US20050214257 Using self assembling peptide amphiphiles in organ or tissue transplant materials
09/29/2005US20050214244 Menopause homeopathic formulations
09/29/2005US20050214243 Feminine homeopathic formulations
09/29/2005US20050214210 Antibodies that immunospecifically bind to TRAIL receptors
09/29/2005US20050214209 Anitcancer and antiproliferative agents; tumor necrosis factor related apoptosis inducing ligand (TRAIL); combination of amino acid sequences from VHCDR1, 2 or 3 with VLCDR1, 2 or 3 of sequence numbers 42 through 53; isolated cells; kits
09/29/2005DE102004012172A1 Ingredient mixing for baked foods. especially for people with weakened immune systems from the environment, includes vegetable fibers, dried algae and biomass and spices
09/29/2005DE102004009325A1 Use of tropisetron having 5-hydroxytryptamine-3 receptor antagonistic activity for preventing the blocking of 5-hydroxytryptamine-3 receptor in organ transplant rejection reaction in transplanted organs e.g. heart, lungs, kidney or liver
09/29/2005CA2562388A1 Emulsion-stabilized preparation
09/29/2005CA2560953A1 Therapeutic agent for auris interna disorder containing il-6 antagonist as active ingredient
09/29/2005CA2560286A1 Substituted quinazoline or pyridopyrimidine derivative
09/29/2005CA2560059A1 Platinum carboxylate anticancer compounds
09/29/2005CA2559646A1 Medicine for prevention or treatment of frequent urination or urinary incontinence
1 ... 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 ... 1151